AGP & DTx Summit: Digital Therapeutics Showcases HbA1c Reduction as Diabetes Care Evolves

Digital Therapeutics at the AGP & DTx Summit

In May 2026, the city of Shenzhen, China hosted the successful 4th AGP & DTx Summit, gathering professionals under the theme "Beyond Glucose." This pivotal event, co-organized by SIBIONICS, brought together an international assembly of experts, healthcare practitioners, researchers, educators, and patient representatives. The summit focused on advancing the dialogue about how Continuous Glucose Monitoring (CGM) data can transition from mere tracking to generating genuine clinical insights that drive treatment decisions and foster meaningful behavioral changes.

Throughout the summit, it was universally acknowledged that CGM should not be relegated to just a monitoring tool. Its real potential lies in its capacity to translate glucose data into actionable clinical insights that can enhance patient care. Professor Andrej Janež presented a progress report from the International Consortium for Research and Development in AGP and DTx, revealing that over the past two years, the research fund has supported 20 studies led by researchers across 14 countries. These studies delve into CGM-related research, exploring accuracy among specific populations, dietary habits, glycemic responses, AI-driven platforms, and clinical monitoring apps.

The vital role of digital therapeutic solutions was underscored by Professor Sofianos Andrikopoulos, who emphasized that DTx can effectively integrate software-driven interventions with lifestyle counseling, treatment support, and comprehensive care models. Evidence shared during the summit highlighted an average reduction in HbA1c levels by 0.54 percentage points attributable to DTx, showcasing its utility in structured diabetes intervention.

From a clinical phenotyping perspective, Professor Wei Qiang illustrated how combining routine input metrics with CGM and AGP data could pinpoint metabolic phenotypes and treatment responses in hospitalized Type 2 diabetes patients, thereby promoting targeted and personalized care.

Professor Shannon Lin also observed that CGM can achieve stable values over time, indicating the necessity for data-driven management. Research demonstrated substantial interest from both clinicians and patients in integrating CGM with AI for predictive analytics and personalized recommendations. Furthermore, Professor Xiao Luo highlighted findings that CGM, combined with Cardiometabolic-Renal Syndrome (CKM), can effectively map glucose and ketone fluctuations during fasting and postprandial cycles, thus simplifying metabolic interventions.

Patient advocate Tom Vesely, living with Type 1 diabetes for nearly 40 years, reminded attendees that CGM amplifies the awareness of daily glucose level variations. However, the ultimate goal should not simply be achieving better time in range, but also enhancing time spent feeling well.

Collectively, these discussions marked a significant shift towards the next phase of diabetes care—moving from solely monitoring to effecting change. The insights gained from this summit will likely pave the way for more integrated and effective diabetes management strategies, aligning with the evolving landscape of patient care in the realm of digital health technologies.

In conclusion, the AGP & DTx Summit has set a crucial precedent for how data and digital therapeutic interventions can enhance patient outcomes in diabetes care, stirring dialogue and innovation within the medical community that resonates well beyond the boundaries of glucose monitoring.